Intellia Therapeutics, Inc
NTLA · Diagnostics · $1.7B
Falling back
Not on a screen at the moment — no base, so no pivot to draw. The price and volume are below.
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The read
Intellia Therapeutics, Inc is not on any of the screens right now. Its relative strength rating is 16, and it sits in Diagnostics.
Peers
Catalyst roadmap
Nothing dated in the next three months that we can ingest automatically.
Flagged by the market sweep
GappedTape · 2026-09-18
+6.7%
From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.
In the news
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory BoardGlobeNewswire Inc. · 2 days agoIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionGlobeNewswire Inc. · 2026-09-04Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswire Inc. · 2026-09-04Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool · 2026-08-31
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray